Literature DB >> 29596116

The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation.

Camille N Kotton1, Deepali Kumar2, Angela M Caliendo3, Shirish Huprikar4, Sunwen Chou5, Lara Danziger-Isakov6, Atul Humar7.   

Abstract

Despite recent advances, cytomegalovirus (CMV) infections remain one of the most common complications affecting solid organ transplant recipients, conveying higher risks of complications, graft loss, morbidity, and mortality. Research in the field and development of prior consensus guidelines supported by The Transplantation Society has allowed a more standardized approach to CMV management. An international multidisciplinary panel of experts was convened to expand and revise evidence and expert opinion-based consensus guidelines on CMV management including prevention, treatment, diagnostics, immunology, drug resistance, and pediatric issues. Highlights include advances in molecular and immunologic diagnostics, improved understanding of diagnostic thresholds, optimized methods of prevention, advances in the use of novel antiviral therapies and certain immunosuppressive agents, and more savvy approaches to treatment resistant/refractory disease. The following report summarizes the updated recommendations.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29596116     DOI: 10.1097/TP.0000000000002191

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  181 in total

1.  A Novel Case of Cytomegalovirus Pneumonia in an Acquired Thrombotic Thrombocytopenic Purpura Patient Treated With Rituximab.

Authors:  Emad Kandah; Raghunandan Konda; Atefeh Kalantary; Adan Madadha; Arvind Kunadi
Journal:  Cureus       Date:  2021-03-30

Review 2.  Risk of cytomegalovirus transmission by blood products after solid organ transplantation.

Authors:  Deborah Jebakumar; Patti Bryant; Walter Linz
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-04-23

Review 3.  Standardization of Nucleic Acid Tests: the Approach of the World Health Organization.

Authors:  S A Baylis; P Wallace; E McCulloch; H G M Niesters; C M Nübling
Journal:  J Clin Microbiol       Date:  2019-01-02       Impact factor: 5.948

4.  Choice of Study Populations for Vaccines.

Authors:  Paul Griffiths; Brenna Hughes
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

5.  A clinically relevant murine model unmasks a "two-hit" mechanism for reactivation and dissemination of cytomegalovirus after kidney transplant.

Authors:  Zheng Zhang; Longhui Qiu; Shixian Yan; Jiao-Jing Wang; Paul M Thomas; Manoj Kandpal; Lihui Zhao; Andre Iovane; Xue-Feng Liu; Edward B Thorp; Qing Chen; Mary Hummel; Yashpal S Kanwar; Michael M Abecassis
Journal:  Am J Transplant       Date:  2019-05-14       Impact factor: 8.086

6.  Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipients.

Authors:  Hannah Imlay; Allison O Dumitriu Carcoana; Cynthia E Fisher; Beatrice Wong; Robert M Rakita; Daniel P Fishbein; Ajit P Limaye
Journal:  Transpl Infect Dis       Date:  2020-02-20       Impact factor: 2.228

7.  Acyclovir for Mechanically Ventilated Patients With Herpes Simplex Virus Oropharyngeal Reactivation: A Randomized Clinical Trial.

Authors:  Charles-Edouard Luyt; Jean-Marie Forel; David Hajage; Samir Jaber; Sophie Cayot-Constantin; Thomas Rimmelé; Elisabeth Coupez; Qin Lu; Mamadou Hassimiou Diallo; Christine Penot-Ragon; Marc Clavel; Carole Schwebel; Jean-François Timsit; Jean-Pierre Bedos; Caroline Hauw-Berlemont; Jérémy Bourenne; Julien Mayaux; Jean-Yves Lefrant; Jean-Paul Mira; Alain Combes; Michel Wolff; Jean Chastre; Laurent Papazian
Journal:  JAMA Intern Med       Date:  2020-02-01       Impact factor: 21.873

8.  Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.

Authors:  Nina Singh; Drew J Winston; Raymund R Razonable; G Marshall Lyon; Fernanda P Silveira; Marilyn M Wagener; Terry Stevens-Ayers; Bradley Edmison; Michael Boeckh; Ajit P Limaye
Journal:  JAMA       Date:  2020-04-14       Impact factor: 56.272

9.  Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.

Authors:  Lauren Cherrier; Aasya Nasar; Kellie J Goodlet; Michael D Nailor; Sofya Tokman; Sunwen Chou
Journal:  Am J Transplant       Date:  2018-10-29       Impact factor: 8.086

10.  Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection.

Authors:  Sunwen Chou; Jingyang Wu; Kening Song; Tien Bo
Journal:  Antiviral Res       Date:  2019-09-27       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.